Gene Therapy, Cell Therapy and Vaccine Discovery and Development

mRNA Vaccine Development GMP-Grade RNA EnzymesIVT RNA PolymerasemRNA Synthesis and Capping Gene Therapy GMP GMP-Grade Gene EditingGMP Cas9 and Cas12a Read More...

Drug and Therapy Discovery and Development

Cell, Gene Therapy and Vaccine Development Cell Therapy ProteinsGMP-Grade RNA EnzymesGMP-Grade Gene Editing Biosimilars and Small Molecules Biosimilars Small Molecule Read More...

Antibody and Protein Production Tools

Antibody Development VLPs and Nanodiscs Custom Services Cloning and Expression Systems Lentiviral, AAV and Non-ViralCell-Free In Vitro TranslationRestriction, Modifying Enzymes Read More...

Drugs and Therapeutics Development – GPCR Focus

Transmembrane Protein Nanodiscs and Virus Like Particles VLPs and NanodiscsGPRC5D ProteinsMRGPRX2 Proteins Antibodies and Biosimilars Human GPCR Antibodies Biosimilars Reporter Read More...

GMP-Grade RNA Enzymes

GMP-Grade Enzymes for mRNA Production Restriction Enzymes, In Vitro Transcription, Capping, Tailing, Circularization ProductsT7 RNA Polymerase (GMP-Grade)Pyrophosphatase, Inorganic (GMP-Grade)RNase RT4 Read More...

Gene Editing Reagents

Explore our GMP-Grade CRISPR Cas9, Cas12a, MaxNuclease, AAV ELISA Kits, and DNA Amplification Enzymes ProductsAccuBase™ Base Editor, GMP-GradeAccuBase™ Base Editor, Read More...

Recombinant Proteins

Comprehensive portfolio of target proteins designed for every stage of antibody drug discovery campaigns ProductsFc ReceptorsCD3 ProteinsFGFRsCD47 & SIRPVLP & Read More...

Cell Therapy Proteins

MHC Complexes, CAR-T Targets, VLPs, Cytokines, and Laminin 521 ProductsCAR-T TargetsCytokinesSoluble TCR Expression ServicesMHC Tetramers & MonomersPeptide-ready MHCsHLA-G and LILRsLaminin Read More...

Base editing technology leads a new chapter in drug development

View All Products Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug Read More...

MSLN Targeted Drugs Entering the Fast Lane

View All Products Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen Read More...

Exploring the Role of MICA in Tumor Immunity and Targeted Therapies

Contact UsView All Products MICA, also known as MHC Class I Polypeptide-Related Sequence A, is a type I MHC molecule Read More...

New advances in CRISPR gene therapy drugs

Contact UsView All Products On April 3, 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced the completion of the rolling biologics Read More...